Evidence map›Paper›PMID 35817945›Full record

Observational studyAdvances in therapy2022

One-Year Outcomes with Use of Anti-T-Lymphocyte Globulin in Patients Undergoing Kidney Transplantation: Results from a Prospective, Multicentric, Observational Study from India.

Sishir Gang, Sanjeev Gulati, Anil K Bhalla, Prem P Varma, Ravi Bansal, Abi Abraham, Deepak S Ray, Mammen M John, Shyam B Bansal, Raj K Sharma and 2 more

Erratum issuedOpen access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Sishir GangDepartment of Nephrology, Muljibhai Patel Urological Hospital, Nadiad, Gujarat, India. sishirgang@hotmail.com.
Sanjeev GulatiDepartment of Nephrology, Fortis and Escorts Group of Hospitals, NCR, New Delhi, India.
Anil K BhallaDepartment of Nephrology, Sir Gangaram Hospital, Rajinder Nagar, New Delhi, India.
Prem P VarmaDepartment of Nephrology, Venkateshwar Hospital, New Delhi, India.
Ravi BansalDepartment of Nephrology, PSRI Hospital, New Delhi, India.
Abi AbrahamDepartment of Nephrology, Lakeshore Hospital and Research Centre Ltd, Ernakulam, Kerala, India.
Deepak S RayDepartment of Nephrology, NH Rabindranath Tagore International Institute of Cardiac Sciences, Eastern Metropolitan Bypass, Mukundapur, Kolkata, India.
Mammen M JohnDepartment of Nephrology, Medical Trust Hospital, Pallimukku, Kochi, Kerala, India.
Shyam B BansalMedanta's Institute of Nephrology and Kidney Transplant, Gurgaon, India.
Raj K SharmaMedanta-The Medicity Hospital, Lucknow, India.
S VishwanathDepartment of Nephrology, Manipal Hospital, Bengaluru, India.
ATLG Registry Investigators Group
Fortis Escorts Hospital · INLakeshore Hospital · INManipal Hospital · INMedanta The Medicity · INMedanta The Medicity · INMedical Trust Hospital · INMuljibhai Patel Urological Hospital · INPushpawati Singhania Research Institute · INRabindranath Tagore International Institute of Cardiac Sciences · INSir Ganga Ram Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLarge-scale Indian data on the use of anti-T-lymphocyte globulin (ATLG) (Grafalon

methodsIn a prospective, multicentric, observational study, adult patients who underwent ABO-compatible KT and had received ATLG as a part of induction were included in the study. The primary outcome measure was overall survival and death-censored graft survival at 12 months. The primary safety outcome was assessed by development of infectious complications and graft rejection.

resultsIn total, 359 patients were included in this study. The mean age was 42.77 ± 12.30 years and 83% were male. The average ATLG dose per patient was 6.2 ± 2.2 mg/kg whereas average cumulative dose per patient was 389.6 ± 149.8 mg. The rate of graft dysfunction was 13.4% of patients and 6.7% had biopsy-proven acute rejection (BPAR). There were a total of 12 (3.3%) deaths and one graft loss. Overall survival and death-censored graft survival at 12 months were 96.65% and 99.44%, respectively. The rate of infections was 13.6% with urinary tract infections being most common.

conclusionATLG at an average dose of 6 mg/kg is an effective and safe induction regimen immunosuppressant for ABO-compatible KT with favourable impact on survival and graft function in Indian patients.

Indexed as

Kidney TransplantationAdultFemaleGraft RejectionHumansImmunosuppressive AgentsLymphocytesMaleMiddle AgedProspective StudiesImmunosuppressive AgentsAnti-T-lymphocyte globulinGrafalonKidney transplantSurvival

Identifiers

PMID35817945
PMCPMC9464724
OpenAlexW4285008644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.